Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.
Snyder LB, Neklesa TK, Willard RR, Gordon DA, Pizzano J, Vitale N, Robling K, Dorso MA, Moghrabi W, Landrette S, Gedrich R, Lee SH, Taylor ICA, Houston JG.
Snyder LB, et al. Among authors: taylor ica.
Mol Cancer Ther. 2024 Dec 13. doi: 10.1158/1535-7163.MCT-23-0655. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 39670468